{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T19:23:04Z","timestamp":1699903384824},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,1,19]],"date-time":"2008-01-19T00:00:00Z","timestamp":1200700800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1007\/s12032-008-9039-1","type":"journal-article","created":{"date-parts":[[2008,1,18]],"date-time":"2008-01-18T14:34:48Z","timestamp":1200666888000},"page":"323-330","source":"Crossref","is-referenced-by-count":14,"title":["Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer"],"prefix":"10.1007","volume":"25","author":[{"given":"J. Kay","family":"Noel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila","family":"Crean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet E.","family":"Claflin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gayatri","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Linz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,1,19]]},"reference":[{"key":"9039_CR1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/gut.52.1.144","volume":"52","author":"DW Hommes","year":"2003","unstructured":"Hommes DW, Peppelenbosch MP, van Deventer SJH. Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut 2003;52:144\u201351.","journal-title":"Gut"},{"key":"9039_CR2","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1182\/blood-2002-12-3647","volume":"101","author":"LC. Plantanias","year":"2003","unstructured":"Plantanias LC. Map kinase signaling pathways and hematologic malignancies. Blood 2003;101:4667\u201379.","journal-title":"Blood"},{"key":"9039_CR3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0065-230X(04)92005-2","volume":"92","author":"DV Bulavin","year":"2004","unstructured":"Bulavin DV, Fornace AJ Jr. P38 MAP kinase\u2019s emerging role as a tumor suppressor. Adv Cancer Res 2004;92:95\u2013118.","journal-title":"Adv Cancer Res"},{"key":"9039_CR4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.molmed.2004.01.007","volume":"10","author":"JM Olson","year":"2004","unstructured":"Olson JM, Hallahan AR. P38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med 2004;10:125\u20139.","journal-title":"Trends Mol Med"},{"key":"9039_CR5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-3-0348-8012-1_2","volume":"60","author":"RM. Schultz","year":"2003","unstructured":"Schultz RM. Potential of p38 MAP kinase inhibitors in the treatment of cancer. Prog Drug Res 2003;60:59\u201392.","journal-title":"Prog Drug Res"},{"key":"9039_CR6","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood-2002-06-1874","volume":"101","author":"T Hideshima","year":"2003","unstructured":"Hideshima T, et\u00a0al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood 2003;101:703\u20135.","journal-title":"Blood"},{"key":"9039_CR7","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2000.18.3.684","volume":"18","author":"EA Eisenhauer","year":"2005","unstructured":"Eisenhauer EA, O\u2019Dwyer PJ, Christian M, Humphrey JS. Phase I clinical trial design in cancer drug development. J Clin Oncol 2005;18:684\u201392.","journal-title":"J Clin Oncol"},{"key":"9039_CR8","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMsa042220","volume":"352","author":"E Horstmann","year":"2005","unstructured":"Horstmann E, McCabe MS, Grochow L, et\u00a0al. Risks and benefits of Phase I oncology trials, 1991 through 2002. N Engl J Med 2005;352:895\u2013904.","journal-title":"N Engl J Med"},{"key":"9039_CR9","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1001\/jama.292.17.2130","volume":"292","author":"TG Roberts","year":"2004","unstructured":"Roberts TG, et\u00a0al. Trends in the risks and benefits to patients with cancer participating in Phase I clinical trials. JAMA 2004;292:2130\u201340.","journal-title":"JAMA"},{"key":"9039_CR10","unstructured":"Alderson P, Green S, Higgins JPT, editors. Cochrane collaboration handbook 4.2.1 [updated December 2003]. Chichester, UK: John Wiley & Sons, 2004 [The Cochrane Library, Issue 1, 2004]."},{"key":"9039_CR11","doi-asserted-by":"crossref","first-page":"376","DOI":"10.7326\/0003-4819-126-5-199703010-00006","volume":"126","author":"DJ Cook","year":"1997","unstructured":"Cook DJ, Mulrow CD, Haynes RG. Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med 1997;126:376\u201380.","journal-title":"Ann Intern Med"},{"key":"9039_CR12","doi-asserted-by":"crossref","unstructured":"Baz R, et\u00a0al. Aspirin decreases the throbotic complications (DVT) of liposomal doxorubicin, vincristine, decreased frequency dexamethasone and thalidomide (DVd-T) treatment of multiple myeloma (MM). Proc ASH 2004, abstract 2397.","DOI":"10.1182\/blood.V104.11.2397.2397"},{"key":"9039_CR13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/10245330290020126","volume":"7","author":"SJ Bowcock","year":"2002","unstructured":"Bowcock SJ, Rassam SM, Ward SM, Turnder JT, Laffan M. Thromboembolism in patients on thalidomide for myeloma. Hematology 2002;7:51\u20133.","journal-title":"Hematology"},{"key":"9039_CR14","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00277-004-0891-6","volume":"83","author":"A Corso","year":"2004","unstructured":"Corso A, et\u00a0al. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol 2004;83:588\u201391.","journal-title":"Ann Hematol"},{"key":"9039_CR15","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1538-7836.2003.00083.x","volume":"1","author":"MC Minnema","year":"2003","unstructured":"Minnema MC, Fijnheer R, de Groot PG, Lokhorst HM. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003;1:445\u20139.","journal-title":"J Thromb Haemost"},{"key":"9039_CR16","unstructured":"Moehler TM, et\u00a0al. Low incidence of deep vein thrombosis in poor prognosis multiple myeloma patients treated with thalidomide and CED chemotherapy. Proc ASH 2002, abstract 5136."},{"key":"9039_CR17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1600-0609.2004.00393.x","volume":"74","author":"M Streetly","year":"2005","unstructured":"Streetly M, et\u00a0al. Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis. Eur J Haematol 2005;74:293\u20136.","journal-title":"Eur J Haematol"},{"key":"9039_CR18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3816\/CLM.2003.n.011","volume":"4","author":"M Zangari","year":"2003","unstructured":"Zangari M, et\u00a0al. Thalidomide and deep vein thrombosis in multiple myeloma: Risk factors and effect on survival. Clin Lymphoma 2003;4:32\u20135.","journal-title":"Clin Lymphoma"},{"key":"9039_CR19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1365-2141.2004.05078.x","volume":"126","author":"M Zangari","year":"2004","unstructured":"Zangari M, et\u00a0al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: Effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004;126:715\u201321.","journal-title":"Br J Haematol"},{"key":"9039_CR20","unstructured":"Caravita T, et\u00a0al. Thalidomide induced neuropathy in patients treated for multiple myeloma. Proc ASH 2002, abstract 5105."},{"key":"9039_CR21","first-page":"75","volume":"45","author":"S Laaksonen","year":"2005","unstructured":"Laaksonen S, Remes K, Kosela K, Voipio-Pulkki LM, Falck B. Thalidomide therapy and polyneuropathy in myeloma patients. Electromyogr Clin Neurophysiol 2005;45:75\u201386.","journal-title":"Electromyogr Clin Neurophysiol"},{"key":"9039_CR22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1600-0609.2004.00382.x","volume":"74","author":"P Tosi","year":"2005","unstructured":"Tosi P, et\u00a0al. Neurological toxicity of long-term (>1\u00a0yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 2005;74:212\u20136.","journal-title":"Eur J Haematol"},{"key":"9039_CR23","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1532\/IJH97.03136","volume":"79","author":"Y Hattori","year":"2004","unstructured":"Hattori Y, Kakimoto T, Okamoto S, Sato N, Ideka Y. Thalidomide-induced severe neutropenia during treatment of multiple myeloma. Int J Haematol 2004;79:283\u201388.","journal-title":"Int J Haematol"},{"key":"9039_CR24","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1067\/mjd.2003.87","volume":"48","author":"VC Hall","year":"2003","unstructured":"Hall VC, El-Azhary RA, Bouwhuis S, Rajkumar SV. Dermatologic side effects of thalidomide in patients with multiple myeloma. J Am Acad Dermatol 2003;48:548\u201352.","journal-title":"J Am Acad Dermatol"},{"key":"9039_CR25","unstructured":"Badros A, et\u00a0al. Hypothyroidism in patients with multiple myeloma (MM) receiving thalidomide. Proc ASH 2000, abstract 4973."},{"key":"9039_CR26","unstructured":"Pavlick AC, Gershenhorn B. Lymphopenia and herpes zoster infections in metastatic melanoma patients treated with temozolomide and thalidomide. Proc ASCO 2003, abstract 2866."},{"key":"9039_CR27","first-page":"421","volume":"8","author":"C Dominguez","year":"2005","unstructured":"Dominguez C, Powers DA, Tamayo N. p38 MAP kinase inhibitors: Many are made, but few are chosen. Curr Opin Drug Discov Deve 2005;8:421\u201330.","journal-title":"Curr Opin Drug Discov Deve"},{"key":"9039_CR28","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","volume":"4","author":"JB Bartlett","year":"2004","unstructured":"Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004;4:314\u201322.","journal-title":"Nat Rev Cancer"},{"key":"9039_CR29","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","volume":"91","author":"RJ D\u2019Amato","year":"1994","unstructured":"D\u2019Amato RJ, Loughnan MD, Flunn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"9039_CR30","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, et\u00a0al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565\u201371.","journal-title":"N Engl J Med"},{"key":"9039_CR31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1586\/14737140.5.1.25","volume":"5","author":"MA. Hussein","year":"2005","unstructured":"Hussein MA. Thalidomide: present and future in multiple myeloma. Expert Rev Anticancer Ther 2005;5:25\u201331.","journal-title":"Expert Rev Anticancer Ther"},{"key":"9039_CR32","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/107327480301000504","volume":"10","author":"D. Weber","year":"2003","unstructured":"Weber D. Thalidomide and its derivatives: New promise for multiple myeloma. Cancer Control 2003;10:375\u201383.","journal-title":"Cancer Control"},{"key":"9039_CR33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1359-6446(04)03307-0","volume":"10","author":"SK Teo","year":"2005","unstructured":"Teo SK, Stirling DI, Zeldis JB. Thalidomide as a novel therapeutic agent: New uses for an old product. Drug Discov Today 2005;10:107\u201314.","journal-title":"Drug Discov Today"},{"key":"9039_CR34","first-page":"194","volume":"1","author":"IM Ghobrial","year":"2003","unstructured":"Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J Supp Oncol 2003;1:194\u2013205.","journal-title":"J Supp Oncol"},{"key":"9039_CR35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/pmj.79.929.127","volume":"79","author":"JN Gordon","year":"2003","unstructured":"Gordon JN, Goggin PM. Thalidomide and its derivatives: Emerging from the wilderness. Postgrad Med J 2003;79:127\u201332.","journal-title":"Postgrad Med J"},{"key":"9039_CR36","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0890-6238(93)90025-3","volume":"7","author":"L Newman","year":"1993","unstructured":"Newman L, et\u00a0al. Assessment of the effectiveness of animal developmental toxicity testing for human safety. Reprod Toxicol 1993;7:359\u201390.","journal-title":"Reprod Toxicol"},{"key":"9039_CR37","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0149-2918(00)88289-2","volume":"21","author":"J Zeldis","year":"1999","unstructured":"Zeldis J, et\u00a0al. S.T.E.P.S.\u2122: A comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999;21:319\u201330.","journal-title":"Clin Ther"},{"key":"9039_CR38","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","volume":"352","author":"A List","year":"2005","unstructured":"List A, et\u00a0al. Effiacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549\u201357.","journal-title":"N Engl J Med"},{"key":"9039_CR39","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1200\/JCO.2004.10.052","volume":"22","author":"SA Schey","year":"2004","unstructured":"Schey SA, et\u00a0al. Phase I study of an immunomodulatory thalidomide analog, CC-4017, in relapsed or refractory multiple myeloma. J Clin Oncol 2004;22:3269\u201376.","journal-title":"J Clin Oncol"},{"key":"9039_CR40","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, et\u00a0al. BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099\u2013109.","journal-title":"Cancer Res"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-008-9039-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-008-9039-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-008-9039-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T22:43:12Z","timestamp":1588286592000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-008-9039-1"}},"subtitle":["A systematic review of the literature"],"short-title":[],"issued":{"date-parts":[[2008,1,19]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["9039"],"URL":"https:\/\/doi.org\/10.1007\/s12032-008-9039-1","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,19]]}}}